Navigation Links
Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
Date:9/26/2011

MISSISSAUGA, Ontario, Sept. 26, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX), announced today that it intends to raise its takeover offer for Afexa Life Sciences Inc. (TSX:FXA) of Edmonton, Alberta to $0.85 per common share, an increase of 20% from $0.71 originally offered under an agreement announced on August 30, 2011.  The increased offer is subject to Afexa's agreement to certain amendments to the support agreement, including a reduction in the minimum tender condition, which Valeant hopes to resolve in the coming days.

"We have decided to offer a premium to Paladin Labs' most recent proposal as we are able to attribute more value than Paladin to the Afexa business given both our larger scale and resources in Canada, coupled with our extensive international consumer footprint," stated J. Michael Pearson, chairman and chief executive officer. "While we normally don't participate in an auction process, given that our existing offer has the full support of the Board and Management of Afexa, we felt it was appropriate to continue to respond quickly to Paladin's hostile overtures."  

Stikeman Elliott LLP is acting as legal counsel to Valeant and RBC Capital Markets is acting as financial advisor to Valeant.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. is a multi-national specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report filed with the SEC and risks and uncertainties as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. These risks and uncertainties also include, without limitation, the ability to reach agreement with Afexa to certain modifications of the support agreement, obtain all necessary regulatory approvals, third party consents and otherwise satisfy the conditions of the offer for shares of Afexa (the "Offer"), delays in mailing the take-over bid documentation and closing the Offer. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect the events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
2. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
3. Valeant Pharmaceuticals to Present at Industry Conferences
4. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
5. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
6. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
7. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
8. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
9. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
10. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
11. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/12/2017)... and Canada joint tech company Laughing Face has ... detergent, and features a powerful disinfection process. The company ... washes and sanitizes women,s panties or babies, cloth diapers in 25 ... ... an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 21, 2017 , ... ... together a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity ... Equity is the third book from a recent series of from this ...
(Date:5/21/2017)... ... May 21, 2017 , ... Dental visits are ... months since you've seen a dentist, it's time for a dental checkup. The ... once per year. , Dental checkups are a relatively easy procedure that involves ...
(Date:5/19/2017)... City, Mo (PRWEB) , ... May 19, 2017 , ... ... Saturday, May 20, his name will already appear on two major research studies that ... has been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... class of Beckman Young Investigators: , Victor Acosta, Ph.D. - University of New ... Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata ...
(Date:5/19/2017)... ... May 18, 2017 , ... CloSYS products which are marketed ... while extremely helpful for mouth and gum health, which is linked to one’s overall ... customers learned quickly of the powerful ways in which CloSYS products immediately helped eliminate ...
Breaking Medicine News(10 mins):